Stryker has just announced the results of the TREVO Study at the International Stroke Conference in New Orleans. TREVO, (Thrombectomy REvascularization of large Vessel Occlusions in acute ischemic stroke) was designed to evaluate Trevo® System’s ability to remove the blood clots that cause strokes, restoring the blood flow to the brain, and was one of the first prospective multi-center clinical studies of clot-removing stent retriever technology.
The study involved sixty patients at seven leading European stroke centers. An independent core lab measured revascularization.
According to Professor Nils Wahlgren, co-Principal Investigator of the Study and Professor of Neurology at Karolinska University Hospital in Solna, Sweden, the results showed high revascularization rates in 91.7% of patients, with 46% of the patients achieving a good outcome in only 7 days, which increased to 55% at 90 days.
Patients who achieved good outcomes were functionally independent, scoring 2 or less on the modified Rankin scale. 5% of patients had a low symptomatic intracranial hemorrhage.
Professor Wahlgren declared:
“The TREVO Study represents an important step forward in the evidence supporting the treatment of patients with moderate and severe strokes with mechanical thrombectomy devices, such as the Trevo System.
The rigorous conduct of this prospective multicenter trial provides more confidence not only in patient selection, but in the successful procedural and clinical outcomes that can be achieved for these patients.”
Clinical evidence is of major importance in achieving a wider adoption of interventional, device-based therapies for treating Acute Ischemic Stroke, and Stryker’s prospective design and thorough conduct of the TREVO Study highlights the company’s commitment of building robust evidence so that important technologies like the Trevo System can be widely used by physicians for the benefit of stroke patients.
Written by Petra Rattue